– YourBio Health from Boston develops a personal health information company, raised $21M in funding.
– Series A round was led by Flagship Pioneering with participation from Newpath Partners.
– The company intends to use the funds to accelerate growth and support forthcoming product launches.

– Laronde is a Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body.
– The company raised $440m in Series B financing.
– The round was led by Flagship Pioneering, with participation from T. Rowe Price Associates, Inc., Invus, Canada Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, funds and accounts managed by BlackRock, and Federated Hermes Kaufmann Funds, among others.
– The new investment will be used to advance the development of the company’s eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

– Ring Therapeutics is a Cambridge, Mass.-based life sciences company.
– The company raised $117m in Series B funding.
– Backers included Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises, alongside Flagship Pioneering.
– The new investment will be used for the continued development and expansion of its novel vector Anellogy™ platform.

– Invaio Sciences, Inc. announced the closing of a Series C financing round totaling $88.9 million.
– The round was led by Flagship Pioneering with Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others joining as new investors.
– With this financing, Invaio has raised more than $142 million since its founding in 2018.
– Invaio is focused on unlocking the potential of the planet’s interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges.

– Inari, a Cambridge, Mass.-based developer of a platform to enable yield increase, raised $208m in Series D funding.
– The round was co-led by Flagship Pioneering with participation from Alexandria Venture Investments, Investment Corporation of Dubai, Banque Pictet on behalf of their clients and Rivas Capital and new investors G Squared and Pavilion Capital.
– The company intends to use the funds to further accelerate advancements across its science platform and product development for corn and soybeans in both North and South America.
– Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Massachusetts, with additional sites in West Lafayette, Indiana, and Ghent, Belgium.

– Valo, a cancer immunotherapy company, raised $110m in Series B funding.
– The round was led by Koch Disruptive Industries and joined by existing investors Flagship Pioneering, Third Rock Ventures, and others.
– It brings Valo to a valuation of $1.5 billion.